Patient capital is often described as a virtue. We prefer to think of it as an edge — perhaps the last durable one available to a private investor. Information is now abundant and instantly priced; speed has been commoditised by machines that will always be faster. What remains scarce is the willingness to wait, and the structure that makes waiting possible.
Most market participants cannot afford patience. They answer to redemptions, to benchmarks, to the anxieties of others. Their time horizons are borrowed and therefore short. A family office, by contrast, can hold through the periods when a good asset is simply out of favour — and it is precisely in those periods that lasting value is accumulated.
The advantage is not knowing more than the market. It is being able to disagree with it for longer.
Patience is not passivity. It is a considered refusal to act until the terms are genuinely attractive, followed by the conviction to commit when they are. Much of the discipline lies in the waiting: keeping capital ready, resisting the pull to deploy it merely because it is idle, and accepting that long stretches of apparent inactivity are the price of a rare, decisive move.
There is a cost to this. Patience means forgoing the excitement of the moment and, often, underperforming the crowd for uncomfortable stretches. But compounding rewards those who stay invested in quality and let time do the work that trading cannot. Over a generation, the difference between the patient and the restless is not marginal — it is the whole result.
We would rather be approximately right and slow than precisely wrong and quick. In a world engineered for urgency, that alone is a strategy.